Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study

2015 ◽  
Vol 53 (10) ◽  
pp. 847-854 ◽  
Author(s):  
Olivier J. David ◽  
Maxwell Pryce ◽  
Karin Meiser ◽  
Franck Picard ◽  
Corinne Emotte ◽  
...  
Keyword(s):  
Single Dose ◽  
Renal Impairment ◽  
Severe Renal Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

scholarly journals Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open‐label, single‐dose, parallel‐group study

2019 ◽  
Vol 85 (9) ◽  
pp. 2011-2021 ◽  
Author(s):  
Niladri Chattopadhyay ◽  
Kai Riecke ◽  
Sandra Ligges ◽  
Torsten Zimmermann ◽  
Atef Halabi ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study

2009 ◽  
Vol 31 ◽  
pp. 2459-2469 ◽  
Author(s):  
Ophelia Q.P. Yin ◽  
Neil Gallagher ◽  
Chiaki Tanaka ◽  
Deirdre Fisher ◽  
Venkat Sethuraman ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

An Open-Label, Single-Dose, Parallel-Group Study of the Effects of Chronic Hepatic Impairment on the Safety and Pharmacokinetics of Desvenlafaxine

2013 ◽  
Vol 35 (6) ◽  
pp. 782-794 ◽  
Author(s):  
Susan Baird-Bellaire ◽  
Jessica A. Behrle ◽  
Vernon D. Parker ◽  
Alain Patat ◽  
Jeffrey Paul ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group
Sign in / Sign up

Export Citation Format

Share Document